The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 68.50
Bid: 65.00
Ask: 72.00
Change: 0.00 (0.00%)
Spread: 7.00 (10.769%)
Open: 68.50
High: 68.50
Low: 68.50
Prev. Close: 68.50
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Expansion of European customer base

22 Oct 2018 07:00

RNS Number : 6860E
Feedback PLC
22 October 2018
 

Feedback plc

 

Feedback expands its European customer base with new orders for TexRAD® from prestigious European university hospitals

 

Cambridge, 22 October 2018: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that its operating company, Feedback Medical Ltd, has received a number of new significant orders for TexRAD®, its patented image texture analysis technology, from prestigious university hospitals across Europe.

The orders have come from: Universitair Ziekenhuis Gent, Belgium; Beaujon Hospital, University Hospital Clichy, Service d'Imagerie médicale, France; ICNAS Producao Unip. Lda (Coimbra), Portugal; University of Cagliari - Department of Diagnostic Imaging and Radiology, Italy. This collection of orders represents the first for TexRAD® in Belgium and Portugal.

The initial areas of research range from Crohn's disease, aneurysms and carotid imaging, to liver cancer on routinely acquired standard computed tomography (CT) and magnetic resonance (MR) images. These research projects will run alongside other projects in the area of oncology, which is the main focus area for the Company.

The orders have arisen from an increase in business development activities during the year. These include scientific presentations and peer group referrals from previous purchasers of TexRAD®.

TexRAD® is now used across Europe and the Company is looking to expand its existing customer bases in the US and Asia. As outlined in the recent trading update, the Company has initiated plans for regulatory approval of TexRAD with the US FDA including 510k as medical device and CFR Chapter 21 part 11 compliance for use in clinical trials of drug candidates for FDA marketing approval.

Dr Balaji Ganeshan, Global Business Development Director of Feedback Medical Ltd, said:

"These recent orders of TexRAD® are further validation of Feedback Medical and our technology. We are taking advantage of our growing reputation to drive new business. These new business wins have resulted from having referrals from current customers and penetrating new country markets. TexRAD® is now being used in a diverse range of research fields which demonstrates the significant potential and applicability of our technology."

 

- ENDS -

 

For further information, please contact:

 

Feedback plc

Alastair Riddell, Executive Chairman

Lindsay Melvin, CFO

 

+44 (0)1954 718072

IR@fbk.com

Instinctif Partners

Rozi Morris/ Deborah Bell/ Phillip Marriage

+44 (0)20 7457 2020

feedbackplc@instinctif.com

 

 

 

Notes to editors

 

About Feedback plc

Feedback plc (AIM: FDBK) is a specialist medical imaging technology company providing innovative software and systems, through its fully-owned trading subsidiary, Feedback Medical Limited. Its products advance the work of radiologists, clinicians and medical researchers by improving workflows and giving unique insights into diseases, particularly cancer. Feedback Medical works with customers globally from headquarters in the internationally renowned scientific hub of Cambridge, UK. Its proprietary technologies are TexRAD®, the quantitative texture analysis tool and Cadran, a picture archiving communication system (PACS). For more information, see www.fbk.com

About TexRAD® quantitative texture analysis

TexRAD® is a patent-protected software tool which extracts and quantifies texture features in radiological images, assisting research into all tumour types. In the exciting new field of radiomics, TexRAD® uncovers biomarkers in medical images which are invisible to the naked eye. TexRAD® has featured in over 100 academic publications, won numerous awards and is currently used in over 50 prestigious institutions worldwide. Feedback Medical recently launched TexRAD® Lung, a software tool for the analysis of lung cancer, which is CE marked for clinical use in the EU.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFMMZGGMFGRZZ
Date   Source Headline
29th Apr 20202:00 pmRNSPrice Monitoring Extension
27th Apr 20202:05 pmRNSSecond Price Monitoring Extn
27th Apr 20202:00 pmRNSPrice Monitoring Extension
27th Apr 202011:05 amRNSSecond Price Monitoring Extn
27th Apr 202011:00 amRNSPrice Monitoring Extension
24th Apr 20207:00 amRNSGrant of Options
20th Apr 20207:00 amRNSBleepa rolled out at PAH NHS Trust for Covid-19
26th Mar 20203:52 pmRNSFeedback Medical to offer Bleepa for COVID-19
18th Feb 20207:00 amRNSInterim Results
3rd Feb 202012:21 pmRNSAppointment of Non-Executive Director
21st Jan 202010:30 amRNSChange of Registered Office
13th Jan 20207:00 amRNSLicence agreement with Imaging Engineering
19th Nov 20197:00 amRNSResult of AGM
18th Nov 20197:01 amRNSAGM Statement
18th Nov 20197:00 amRNSFirst Bleepa pilot study initiated with NHS Trust
24th Oct 20198:28 amRNSFinal Results: Revenue up 23%
17th Oct 20197:00 amRNSUpdate re Bleepa®
27th Sep 20192:52 pmRNSStatement re share price
4th Sep 20197:00 amRNSBleepa - the clinical messaging app - at NHS Expo
3rd Sep 20199:46 amRNSHolding(s) in Company
2nd Sep 201912:24 pmRNSHolding(s) in Company
2nd Sep 20197:00 amRNSHolding(s) in Company
30th Aug 20195:00 pmRNSTotal Voting Rights
29th Aug 20192:06 pmRNSResult of General Meeting
29th Aug 20197:00 amRNSBoard Changes
13th Aug 20192:45 pmRNSPosting of Circular and Notice of General Meeting
12th Aug 20197:00 amRNSProposed placing and subscription to raise £2m
7th Aug 201910:47 amRNSStatement re Online Commentary
26th Jul 201912:03 pmRNSBleepa - revolutionising clinical messaging
10th Jul 20197:00 amRNSOutcome of strategic review and trading update
10th Jun 20199:28 amRNSHolding(s) in Company
7th Jun 201910:07 amRNSHolding(s) in Company
25th Apr 20197:00 amRNSTrading update
9th Apr 20197:00 amRNSFeedback Medical CEO appointed Feedback plc CEO
14th Feb 20197:00 amRNSFeedback Medical appoints Dr Tom Oakley as CEO
24th Jan 20197:00 amRNSHalf-year Results
23rd Jan 20192:02 pmRNSResult of AGM
30th Nov 20185:00 pmRNSTotal Voting Rights
29th Nov 20182:37 pmRNSFinal Results
22nd Nov 201812:59 pmRNSFeedback retains industry standard certification
19th Nov 20182:56 pmRNSDirector/PDMR Shareholding
19th Nov 201811:49 amRNSHolding(s) in Company
16th Nov 20189:16 amRNSHolding(s) in Company
15th Nov 201811:35 amRNSResult of General Meeting
1st Nov 20183:11 pmRNSHolding(s) in Company
31st Oct 20185:00 pmRNSTotal Voting Rights
31st Oct 20184:15 pmRNSHolding(s) in Company
29th Oct 20182:44 pmRNSNotice of General Meeting
25th Oct 20187:00 amRNSProposed placing and subscription to raise £1.375m
22nd Oct 20187:00 amRNSExpansion of European customer base

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.